Skip to main content

Table 2 Efficacy indicators

From: Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study

Main efficacy indicators Secondary efficacy measurements
6MWD
HRR1
Pulmonary hypertension WHO classification
Borg Dyspnea Score
Minnesota Living with Heart Failure Questionnaire
NT-proBNP
cTNI
RVSP
Uric acid
Volume of pericardial effusion
Pulmonary artery diameter
Diameter of the same layer of aorta
Arterial oxygen saturation
Time of clinical deterioration
  1. Clinical deterioration is defined as the need to increase medication or change the therapeutic regimen for the treatment of PH, particularly inhaled, intravenous, or subcutaneous application of prostacyclin and its analogues; aggravated symptoms of right heart failure that do not respond to diuretics; atrial septostomy or death; lung transplantation; or hospitalization caused by exacerbation of PH
  2. Other clinical symptoms and signs, biochemical indicators, and imaging indicators are recorded (Table 2) for comprehensive prognostic evaluation and risk assessment